Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | S214fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM S214fs results in a change in the amino acid sequence of the Atm protein beginning at aa 214 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). S214fs has not been characterized, however, due to the effects of other truncation mutations downstream of S214 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM S214fs |
Transcript | NM_000051.4 |
gDNA | chr11:g.(108244095_108244096) |
cDNA | c.(640_639) |
Protein | p.S214fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000051.3 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_005271562.5 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_047426981.1 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_017017792.2 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.(108244095_108244096) | c.(640_639) | p.S214fs | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM S214fs | colorectal cancer | predicted - sensitive | Berzosertib + Irinotecan | Case Reports/Case Series | Actionable | In a Phase I trial, the combination of Berzosertib (VX-970) and Camptosar (irinotecan) was tolerated in patients with advanced solid tumors, and resulted in a 26% tumor decrease lasting 7.5 months in a colorectal cancer patient harboring ATM S214fs (J Clin Oncol 40, 2022 (suppl 16; abstr 3012); NCT02595931). | detail... |